title: Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
abstract: OBJECTIVE
  This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with90Y-[DOTA0, D-Phe1, Tyr3]-octreotate.
  
  
  METHODS
  CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of90Y-[DOTA0, D-Phe1, Tyr3]-octreotate. The primary end point was overall survival.
  
  
  RESULTS
  Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression.
  
  
  CONCLUSIONS
  Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold.
authors.affiliation: Clinical Department of Chemotherapy, Hospital Ministry of the Interior & Administration & Warmia & Mazury Oncology Centre, Olsztyn, Poland.|Department of Medical Science, University of Varmia & Masuria, Olsztyn, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Rogowski
authors.affiliation: Clinical Department of Chemotherapy, Hospital Ministry of the Interior & Administration & Warmia & Mazury Oncology Centre, Olsztyn, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Wachuła
authors.affiliation: Department of Endocrinology, Medical University of Gdańsk, Gdańsk, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Lewczuk
authors.affiliation: Department of Clinical Oncology, Maria-Skłodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Kolasińska-Ćwikła
authors.affiliation: Department of Pathology & Neuropathology, Medical University of Gdańsk, Gdańsk, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Iżycka-Świeszewska
authors.affiliation: Department of Oncology, Pomeranian Medical University, Szczecin, Poland.
authors.forename: Violetta
authors.initials: V
authors.lastname: Sulżyc-Bielicka
authors.affiliation: Department of Medical Science, University of Varmia & Masuria, Olsztyn, Poland.
authors.forename: Jarosław B
authors.initials: JB
authors.lastname: Ćwikła
mesh_terms: D014408:Biomarkers, Tumor; D053379:Chromogranin A / Q000097:blood*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000097:blood* / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D011379:Prognosis; D013274:Stomach Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D053379:Chromogranin A
keywords: chromogranin A; neuroendocrine tumors; prognosis; radionuclide therapy; survival